TESARO, Inc. logo

TESARO, Inc.

TESARO is a biopharmaceutical company devoted to providing transformative therapies to people bravely facing cancer. TESARO is a clinical stage, oncology-focused biopharmaceutical company and companys pipeline is sourced through business development and licensing activities.

[stock_market_widget type=”leaderboard” template=”color-frame” color=”yellow” assets=”TSRO” api=”yf” style=”font-size: 15px”]

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://www.tesarobio.com
Founded2010
Disease Focus
Development Stage
STOCK CODENASDAQ: TSRO
Address
1000 Winter Street St, Suite # 3300, MA, 02451
Waltham
United States
Email
Contact Number
+1 339 970 0900
+ 33 1 78 42 37 97

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/tesaro” connections=”true” suffix=””]

In Mar 2014, AnaptysBio granted TESARO an exclusive rights to its antibody programs targeting PD-1, TIM-3 and LAG-3, including monospecific and dual reactive antibody drug candidates. TESARO paid $17 Mn upfront payment and up to $90 Mn in milestones for approval–on each program.

In Jun 2012, TESARO in-licensed Niraparib/MK-4827, being evaluated in PH I for treatment of solid tumors, from Merck. In Mar 2011, TESARO in-licensed small molecule inhibitors of Anaplastic Lymphoma Kinase (ALK) program from Amgen.

In Dec 2010, TESARO in-licensed worldwide rights to Its lead compound – Rolapitant, currently undergoing PH III for the treatment of chemotherapy induced nausea and vomiting, from OPKO Health, Inc.

Key investors include New Enterprise Associates, InterWest Partners, Kleiner Perkins Caufield & Byers, Venrock, Pappas Ventures, T. Rowe Price, Oracle Partners, Deerfield Management and Leerink Swann.